Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRYOMUNE: Cryoablation + Pembrolizumab + Pemetrexed-carboplatin in Metastatic Lung Adenocarcinoma
NCT04339218Phase 3Recruiting
- Sponsor
- Institut Bergonié
- Start
- Aug 2020
- Primary completion
- Aug 2026
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in lung adenocarcinoma (2 arms), sponsored by Institut Bergonié. Primary endpoint: Overall Survival Rate at 1 year. Started Aug 2020; status: recruiting.
02
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT04339218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339218.